title: The economic impact of rapid Candida species identification by T2Candida among high-risk patients.
abstract: BACKGROUND
  This study estimates the cost-effectiveness and hospital budget impact of rapid candidemia identification using T2Candida, a novel diagnostic panel with same-day species-specific results.
  
  
  METHODS
  A 1-year decision-tree model estimates hospital costs (2013 US$) and effects (candidemia-related deaths) for faster diagnostics versus blood culture (BC), accounting for disease prevalence, distribution of Candida species, test characteristics (sensitivity/specificity/time to result), antifungal medication and differential length-of-stay and mortality by appropriate treatment timing.
  
  
  RESULTS
  The model estimates a hospital with 5100 annual high-risk patients could possibly save $5,858,448 with T2Candida versus BC, a 47.6% decrease in candidemia diagnosis and treatment budget ($1149/patient tested), while averting 60.6% of candidemia-related mortality.
  
  
  CONCLUSIONS
  Hospitals may observe lower candidemia-related inpatient costs and mortality with rapid Candida diagnosis.
authors.affiliation: Health Economics & Outcomes Research, 425 Market Street, 7th Floor, IMS Health, San Francisco, CA 94105, USA.
authors.forename: Sara Pinar
authors.initials: SP
authors.lastname: Bilir
authors.affiliation: Health Economics & Outcomes Research, 425 Market Street, 7th Floor, IMS Health, San Francisco, CA 94105, USA.
authors.forename: Cheryl P
authors.initials: CP
authors.lastname: Ferrufino
authors.affiliation: T2Biosystems, 101 Hartwell Ave, Lexington, MA 02421, USA.|University of Iowa College of Medicine & College of Public Health, Iowa City, IA 52242, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Pfaller
authors.affiliation: Health Economics & Outcomes Research, 425 Market Street, 7th Floor, IMS Health, San Francisco, CA 94105, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Munakata
mesh_terms: D002175:Candida / Q000145:classification* / Q000302:isolation & purification*; D058387:Candidemia / Q000175:diagnosis* / Q000188:drug therapy / Q000191:economics* / Q000401:mortality; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005260:Female; D017721:Hospital Costs; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D016533:Mycological Typing Techniques / Q000191:economics*; D011933:Reagent Kits, Diagnostic / Q000191:economics*; D012306:Risk
chemical_list: D011933:Reagent Kits, Diagnostic
keywords: budget impact; candidemia; cost–effectiveness analysis; economic model; hospital-acquired infection